175 related articles for article (PubMed ID: 3052644)
41. Canadian Red Cross lecture. Current concepts of oxygen-transporting blood substitutes.
Bolin RB
Can J Surg; 1982 Jul; 25(4):422-4. PubMed ID: 7046893
[TBL] [Abstract][Full Text] [Related]
42. [Protective effect of fluosol-DA in acute cerebral ischemia (author's transl)].
Ishikawa R; Peerless SJ; Hunter IG
No Shinkei Geka; 1981 Dec; 9(13):1503-8. PubMed ID: 6808409
[TBL] [Abstract][Full Text] [Related]
43. Initial Canadian experience with artificial blood (Fluosol-DA-20%) in severely anemic patients.
Stefaniszyn HJ; Wynands JE; Salerno TA
J Cardiovasc Surg (Torino); 1985; 26(4):337-42. PubMed ID: 4019576
[TBL] [Abstract][Full Text] [Related]
44. Pulmonary complications after Fluosol administration to patients with life-threatening blood loss.
Police AM; Waxman K; Tominaga G
Crit Care Med; 1985 Feb; 13(2):96-8. PubMed ID: 3967511
[TBL] [Abstract][Full Text] [Related]
45. Rationale for the clinical studies of anemia treated with the perfluorochemical emulsion: Fluosol DA 20%.
Tremper KK
Prog Clin Biol Res; 1983; 122():307-13. PubMed ID: 6348785
[No Abstract] [Full Text] [Related]
46. Clinical studies of a perfluorochemical whole blood substitute (Fluosol-DA) Summary of 186 cases.
Mitsuno T; Ohyanagi H; Naito R
Ann Surg; 1982 Jan; 195(1):60-9. PubMed ID: 7034658
[TBL] [Abstract][Full Text] [Related]
47. Prevention of ischemia during percutaneous transluminal coronary angioplasty by transcatheter infusion of oxygenated Fluosol DA 20%.
Cleman M; Jaffee CC; Wohlgelernter D
Circulation; 1986 Sep; 74(3):555-62. PubMed ID: 2943533
[TBL] [Abstract][Full Text] [Related]
48. The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid, Fluosol-DA.
Tremper KK; Friedman AE; Levine EM; Lapin R; Camarillo D
N Engl J Med; 1982 Jul; 307(5):277-83. PubMed ID: 7045667
[TBL] [Abstract][Full Text] [Related]
49. A comparison of blood and Fluosol-DA for cardiopulmonary bypass.
Rousou JA; Engelman RM; Anisimowicz L; Dobbs WA
J Cardiovasc Surg (Torino); 1985; 26(5):447-53. PubMed ID: 4030876
[TBL] [Abstract][Full Text] [Related]
50. Effects of a transfusion with a blood substitute (Fluosol-DA, 20%) on cerebral circulation in the monkey.
Nagasawa S; Handa H; Naruo Y; Oda Y; Yonekawa Y; Takebe Y
Neurol Res; 1981; 3(3):237-50. PubMed ID: 6122175
[TBL] [Abstract][Full Text] [Related]
51. Therapeutic effect of infused Fluosol-DA/carbogen with ephedrine, flunarizine, or nitroprusside.
Teicher BA; Holden SA; Northey D; Dewhirst MW; Herman TS
Int J Radiat Oncol Biol Phys; 1993 Apr; 26(1):103-9. PubMed ID: 8482616
[TBL] [Abstract][Full Text] [Related]
52. Effects of dose and scheduling on growth delay of the Lewis lung carcinoma produced by the perfluorochemical emulsion, Fluosol-DA.
Teicher BA; Rose CM
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1311-3. PubMed ID: 3093415
[TBL] [Abstract][Full Text] [Related]
53. Fluorocarbon-based in vivo oxygen transport and delivery systems.
Riess JG
Vox Sang; 1991; 61(4):225-39. PubMed ID: 1776239
[TBL] [Abstract][Full Text] [Related]
54. Effect of Fluosol-DA on the response of intracranial 9L tumors to X rays and BCNU.
Teicher BA; Herman TS; Rose CM
Int J Radiat Oncol Biol Phys; 1988 Nov; 15(5):1187-92. PubMed ID: 3141321
[TBL] [Abstract][Full Text] [Related]
55. Effect of hemodilution with dextran, stroma-free hemoglobin solution and fluosol-DA on experimental myocardial ischemia in the dog.
Biro GP
Bibl Haematol; 1981; (47):54-69. PubMed ID: 6175307
[No Abstract] [Full Text] [Related]
56. Oxygenation effect of fluosol-DA on hypoxic tumor tissue and retention of PFCs in the tumor-bearing rats.
Watanabe M; Okamoto H; Ohyanaqi H; Saitoh Y; Yano K; Tsuda Y; Ueda Y; Yokoyama K
Biomater Artif Cells Artif Organs; 1988; 16(1-3):547-56. PubMed ID: 3140922
[TBL] [Abstract][Full Text] [Related]
57. Fluosol DA-20 in the treatment of severe anemia: randomized, controlled study of 46 patients.
Spence RK; McCoy S; Costabile J; Norcross ED; Pello MJ; Alexander JB; Wisdom C; Camishion RC
Crit Care Med; 1990 Nov; 18(11):1227-30. PubMed ID: 1699704
[TBL] [Abstract][Full Text] [Related]
58. Assessment of newly developed perfluorocarbon emulsion: oxygen carrying capacity as the blood substitute in vivo.
Sakanoue J; Tamura M; Fukushima S; Takeuchi Y; Sakuma I; Kitabatake A
Artif Cells Blood Substit Immobil Biotechnol; 2001 Sep; 29(5):389-97. PubMed ID: 11708662
[TBL] [Abstract][Full Text] [Related]
59. Surgical use of fluosol-DA in Jehovah's Witness patients.
Ohyanagi H; Nakaya S; Okumura S; Saitoh Y
Artif Organs; 1984 Feb; 8(1):10-8. PubMed ID: 6703920
[TBL] [Abstract][Full Text] [Related]
60. Increases in brain tumor and cerebral blood flow by blood-perfluorochemical emulsion (Fluosol-DA) exchange.
Hiraga S; Klubes P; Owens ES; Cysyk RL; Blasberg RG
Cancer Res; 1987 Jun; 47(12):3296-302. PubMed ID: 3581070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
